




APPLYING SCIENCE AND OUR GLOBAL RESOURCES TO EXTEND AND SIGNIFICANTLY IMPROVE PATIENTS' LIVES



INNOVATING TREATMENTS TO HELP PATIENTS AROUND THE WORLD

9 R&D Locations in the US...



...and the UK



TOGETHER WITH ASTRAZENECA...

We can seize new opportunities to expand our global research capabilities and partnerships to better serve patients in need.

- Deepen research efforts
- Bolster innovative science
- Speed development of treatments
- Strengthen ability to fight critical diseases:
 - » oncology
 - » immunology and inflammation
 - » cardiovascular and metabolics
 - » vaccines
- Broaden emerging markets footprint

+250

More than 250 R&D partners and institutions around the world

CTI alone has more than 23 academic institutions in its network

INVESTING IN COMMUNITIES AND RESEARCH

"...it's a fantastic opportunity to work in a country with a scientific background and still some world-class universities...Pfizer are serious and they've got a lot of money to spend. They'll need first-class people doing first-class research."¹

- Sir Richard Sykes
Former Chairman and Chief Executive of GlaxoSmithKline
On R&D investment in the UK

¹ SOURCE: Bloomberg (April 29, 2014)

"A combined company would bring together powerful and world leading research expertise in key therapeutic areas ... in which the world class academic research resources in the 'golden triangle' of Oxford, Cambridge and London would represent a vital component..."²

-Ian Read
Pfizer CEO and Chairman
On a potential Pfizer-AstraZeneca combination

² (May 2, 2014)